A5058148727- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Eosinophilic Disorders and Syndromes
- Liver Diseases and Immunity
- Pregnancy and Medication Impact
- Eosinophilic Esophagitis
- Immune Cell Function and Interaction
- Hepatitis C virus research
- Delphi Technique in Research
- Breastfeeding Practices and Influences
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Medical Imaging and Pathology Studies
- Hepatitis B Virus Studies
- Cancer Diagnosis and Treatment
- Asthma and respiratory diseases
- Reproductive System and Pregnancy
- Diabetes and associated disorders
- Sarcoidosis and Beryllium Toxicity Research
- Gastrointestinal disorders and treatments
- Liver Disease Diagnosis and Treatment
University Hospital Southampton NHS Foundation Trust
2023-2024
National Institute for Health Research
2023-2024
NIHR Southampton Biomedical Research Centre
2023
University of Southampton
2016-2023
Background Nintedanib slows progression of lung function decline in patients with progressive fibrosing (PF) interstitial disease (ILD) and was recommended for this indication within the United Kingdom (UK) National Health Service Scotland June 2021 England, Wales Northern Ireland November 2021. To date, there has been no national evaluation use nintedanib PF-ILD a real-world setting. Methods 26 UK centres were invited to take part service between 17 30 September 2022. Summary data regarding...
Natural killer (NK) cells are innate immune that interface with the adaptive system to generate a pro-inflammatory environment. Primary Biliary Cholangitis (PBC) is hepatic autoimmune disorder extrahepatic associations including systemic sclerosis, Sjogren's syndrome and thyroiditis. Immunogenetic studies have identified polymorphisms of IL-12/STAT4 pathway as being associated PBC. As this important for NK cell function we investigated in Circulating from individuals PBC were constitutively...
<h3>Background</h3> In 2020, a Targeted Lung Health Check (TLHC) lung cancer screening pilot launched at our University hospital. Eligible patients (aged 55 to 74) identified high-risk of proceed low-dose CT (LDCT) chest. individuals undergoing LDCT, significant proportion have incidental findings including interstitial abnormalities (ILAs) generating onward referrals. Our aim was evaluate the outcomes those referred from an disease (ILD) service. <h3>Methods</h3> Retrospective analysis...
Despite most of the asthma population having mild disease, phenotype is poorly understood. Here, we aim to address this gap in knowledge by extensively characterising and comparing with difficult-to-treat asthma.We assessed two real-world adult cohorts from South England using an identical methodology: Wessex AsThma CoHort difficult (WATCH) (n=498) a cohort comparator arm Epigenetics Of Severe Asthma (EOSA) study (n=67). Data acquisition included detailed clinical, health disease-related...
Antifibrotic prescribing is changing significantly in the UK with new National Institute for Health and Care Excellence (NICE) guidelines nintedanib IPF set to be published February 2023 (NICE, 2022). There are also inconsistencies between patients PF-ILD. Our aim was evaluate discrepancies anti-fibrotic availability on a national registry using current, future PF-ILD criteria. Permission obtained from British Thoracic Society (BTS) Information Governance Committee access FVC readings BTS...
<b>Background:</b> Nintedanib was approved in the UK for use progressive fibrosing interstitial lung disease (PF-ILD) November 2021.<sup>1</sup> The prescribing criteria defines PF-ILD using diagnostic established by INBUILD study.<sup>2</sup> There has been no national evaluation of nintedanib for PF-ILD a real-world setting. <b>Methods:</b> A service distributed to specialist (ILD) centres September 2022. Local clinical audit department approval obtained. <b>Results:</b> 24...